The Roles of Immuno-modulator Treatment and Echocardiographic Screening in Rheumatic Fever and Rheumatic Heart Disease Control: Research from Aotearoa, New Zealand

Overview

Journal J R Soc N Z

Date 2024 Dec 16

PMID 39677380

Authors

Nigel Wilson

Anneka Anderson

Michael G Baker

Julie Bennett

Adam Dennison

Reuben McGregor

Francis Middleton

Nicole J Moreland

Rachel Webb

Affiliations

Soon will be listed here.

Abstract

This review summarises advances in research from Aotearoa, New Zealand (NZ) that have potential to reduce the inequitable distribution of acute rheumatic fever (ARF) and rheumatic heart disease (RHD). ARF incidence and RHD prevalence are unacceptably inequitable for Māori and Pacifica. Recent qualitative research has demonstrated mismatches between the lived experience of those with ARF/RHD and health service experience they encounter. NZ-led research has contributed knowledge to all stages of disease prevention (primordial, primary and secondary) and for tertiary management. Modifiable risk factors for ARF are racism across health sectors, household crowding, barriers to accessing primary health care, a high intake of sugar-sweetened beverages and preceding sore throat and skin infections. NZ research has evaluated the impact of a large-scale sore throat management programme and Streptococcal A vaccine development. This review highlights two programme domains of research by the authors that have the potential to reduce the burden of chronic RHD: firstly, effective immunomodulation of ARF to reduce the severity of carditis, with current clinical trials of hydroxychloroquine in NZ; secondly, the development of echocardiographic screening of previously undetected RHD. This now meets criteria for an effective screening test and has potential translation for disease control of RHD.

References

Parks T, Kado J, Miller A, Ward B, Heenan R, Colquhoun S . Rheumatic Heart Disease-Attributable Mortality at Ages 5-69 Years in Fiji: A Five-Year, National, Population-Based Record-Linkage Cohort Study. PLoS Negl Trop Dis. 2015; 9(9):e0004033. PMC: 4570761. DOI: 10.1371/journal.pntd.0004033. View

ILLINGWORTH R, Burke J, DOXIADIS S, LORBER J, PHILPOTT M, Stone D . Salicylates in rheumatic fever: an attempt to assess their value. Q J Med. 1954; 23(90):177-213. View

Abrokwa S, Ruby L, Heuvelings C, Belard S . Task shifting for point of care ultrasound in primary healthcare in low- and middle-income countries-a systematic review. EClinicalMedicine. 2022; 45:101333. PMC: 8904233. DOI: 10.1016/j.eclinm.2022.101333. View

Costedoat-Chalumeau N, Amoura Z, Le Thi Huong D, Lechat P, Piette J . Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev. 2005; 4(2):111-5. DOI: 10.1016/j.autrev.2004.11.009. View

Zhang W, Okello E, Nyakoojo W, Lwabi P, Mondo C . Proportion of patients in the Uganda rheumatic heart disease registry with advanced disease requiring urgent surgical interventions. Afr Health Sci. 2016; 15(4):1182-8. PMC: 4765392. DOI: 10.4314/ahs.v15i4.17. View

Ralph A, Webb R, Moreland N, McGregor R, Bosco A, Broadhurst D . Searching for a technology-driven acute rheumatic fever test: the START study protocol. BMJ Open. 2021; 11(9):e053720. PMC: 8444258. DOI: 10.1136/bmjopen-2021-053720. View

Lorenz N, Ho T, McGregor R, Davies M, Williamson D, Gurney J . Serological Profiling of Group A Streptococcus Infections in Acute Rheumatic Fever. Clin Infect Dis. 2021; 73(12):2322-2325. DOI: 10.1093/cid/ciab180. View

Costedoat-Chalumeau N, Dunogue B, Morel N, Le Guern V, Guettrot-Imbert G . Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med. 2014; 43(6 Pt 2):e167-80. DOI: 10.1016/j.lpm.2014.03.007. View

Mirzoev T, Kane S . What is health systems responsiveness? Review of existing knowledge and proposed conceptual framework. BMJ Glob Health. 2017; 2(4):e000486. PMC: 5717934. DOI: 10.1136/bmjgh-2017-000486. View

10.

Marijon E, Ou P, Celermajer D, Ferreira B, Mocumbi A, Jani D . Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med. 2007; 357(5):470-6. DOI: 10.1056/NEJMoa065085. View

11.

Carapetis J, McDonald M, Wilson N . Acute rheumatic fever. Lancet. 2005; 366(9480):155-68. DOI: 10.1016/S0140-6736(05)66874-2. View

12.

Kim M, Martin W, Minigo G, Keeble J, Garnham A, Pacini G . Dysregulated IL-1β-GM-CSF Axis in Acute Rheumatic Fever That Is Limited by Hydroxychloroquine. Circulation. 2018; 138(23):2648-2661. DOI: 10.1161/CIRCULATIONAHA.118.033891. View

13.

Anderson A, Spray J . Beyond awareness: Towards a critically conscious health promotion for rheumatic fever in Aotearoa, New Zealand. Soc Sci Med. 2020; 247:112798. DOI: 10.1016/j.socscimed.2020.112798. View

14.

Wilson N . Echocardiography and subclinical carditis: guidelines that increase sensitivity for acute rheumatic fever. Cardiol Young. 2008; 18(6):565-8. DOI: 10.1017/S1047951108003211. View

15.

Middleton F, McGregor R, Webb R, Wilson N, Moreland N . Cytokine imbalance in acute rheumatic fever and rheumatic heart disease: Mechanisms and therapeutic implications. Autoimmun Rev. 2022; 21(12):103209. DOI: 10.1016/j.autrev.2022.103209. View

16.

Roden D, Harrington R, Poppas A, Russo A . Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment. Circulation. 2020; 141(24):e906-e907. DOI: 10.1161/CIRCULATIONAHA.120.047521. View

17.

Otto H, Saether S, Banteyrga L, Haugen B, Skjaerpe T . High prevalence of subclinical rheumatic heart disease in pregnant women in a developing country: an echocardiographic study. Echocardiography. 2011; 28(10):1049-53. DOI: 10.1111/j.1540-8175.2011.01520.x. View

18.

Perelini F, Blair N, Wilson N, Farrell A, Aitken A . Family acceptability of school-based echocardiographic screening for rheumatic heart disease in a high-risk population in New Zealand. J Paediatr Child Health. 2015; 51(7):682-8. DOI: 10.1111/jpc.12829. View

19.

Moreland N, Waddington C, Williamson D, Sriskandan S, Smeesters P, Proft T . Working towards a group A streptococcal vaccine: report of a collaborative Trans-Tasman workshop. Vaccine. 2014; 32(30):3713-20. DOI: 10.1016/j.vaccine.2014.05.017. View

20.

Giudicessi J, Noseworthy P, Friedman P, Ackerman M . Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc. 2020; 95(6):1213-1221. PMC: 7141471. DOI: 10.1016/j.mayocp.2020.03.024. View